EverSource Wealth Advisors
STLN icon

EverSource Wealth Advisors’s Starling Oncology STLN Stock Holding History

EverSource Wealth Advisors’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$88 Hold
14
– – ﹤0.01% 4415
2026
Q2 		$76 Buy
14
+1
+8% +$4 ﹤0.01% 4329
2026
Q1 		$40 Buy
+13
New +$40 ﹤0.01% 4333

Other funds holding STLN

Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Kingswood Wealth Advisors
Kingswood Wealth Advisors San Diego, California $2.6B AUM 27.46% 1-Year Est. Return
State of Wyoming
State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
T3 Companies
T3 Companies New York $103M AUM 54.73% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Berkshire Money Management
Berkshire Money Management Dalton, Massachusetts $1.16B AUM 13.8% 1-Year Est. Return
Granite Investment Partners
Granite Investment Partners El Segundo, California $1.84B AUM 35.93% 1-Year Est. Return
Pekin Hardy Strauss
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 25.53% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

EverSource Wealth Advisors's STLN Position: Q3 2026 in Review

EverSource Wealth Advisors held its Starling Oncology (STLN) position steady in Q3 2026 at 14 shares worth $88. The position accounts for ﹤0.01% of the portfolio, ranked #4415.

EverSource Wealth Advisors first reported a position in STLN in Q1 2026 and has held it in 3 quarters since. 25 funds tracked by Wall St. Rank hold STLN as of Q3 2026.

  • EverSource Wealth Advisors held 14 shares of Starling Oncology worth $88 as of Q3 2026.
  • EverSource Wealth Advisors left its Starling Oncology share count unchanged in Q3 2026.
  • Starling Oncology made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q3 2026, its #4415 holding.
  • EverSource Wealth Advisors first reported a position in Starling Oncology in Q1 2026 and has held it in 3 quarters since.
  • 25 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2026.

Based on EverSource Wealth Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.